Clinical Trials Logo

Rhinitis, Allergic, Nonseasonal clinical trials

View clinical trials related to Rhinitis, Allergic, Nonseasonal.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01700192 Completed - Clinical trials for Rhinitis, Allergic, Perennial

Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

Start date: January 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults. The primary hypothesis of this study is that administration of MK-8237, compared to placebo, results in significant reduction in the average total combined rhinitis score (TCRS).

NCT ID: NCT01678807 Completed - Clinical trials for Rhinitis, Allergic, Perennial

Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)

Start date: October 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of two doses (6 Development Units [DU] and 12 DU) of MK-8237 sublingual tablets compared to Placebo in adolescents with house dust mite-induced allergic rhinitis/rhinoconjunctivitis. The primary hypothesis is that at least one dose of MK-8237 sublingual tablet is safe and well-tolerated in adolescents with house dust mite-induced allergic rhinitis/rhinoconjunctivitis.

NCT ID: NCT01644617 Completed - Clinical trials for Rhinitis, Allergic, Perennial

A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

Start date: October 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the dose-related effectiveness, the safety and the tolerability of MK-8237, compared to placebo, in the treatment of house dust mite (HDM)-induced allergic rhinitis/rhinoconjunctivitis in adults. The primary hypothesis is that administration of MK-8237, compared to placebo, results in dose-related improvement in the average total nasal symptom score (TNSS) determined during environmental exposure chamber (EEC) challenge.

NCT ID: NCT00041821 Completed - Clinical trials for Rhinitis, Allergic, Nonseasonal

Nasal Irritation Study: Individual Factors in Nasal Irritant Sensitivity

Start date: September 2000
Phase: N/A
Study type: Interventional

This study seeks to document differences in nasal irritant sensitivity within the population. The investigators are interested in knowing whether age, gender, and allergy status (nasal allergies) predict nasal irritant sensitivity. This is important in understanding symptom reporting patterns in air pollution situations (particularly in so-called "problem buildings"), as well as in understanding the reflex mechanism of a response of the nose to irritants (e.g., nasal congestion).